Chronic Kidney Disease, Circulating Ceramides, and Coronary Microvascular Dysfunction: Insights from the CRUISE-MET Study
Cardiorenal Medicine · 2026
DOI: 10.1159/000552268 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cardiorenal Medicine, 2026. Verfasst von Qiang Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences and Peking Union Medical College, Beiji…. Hauptthemen laut MEDLINE: Ceramides, Coronary Artery Disease, Microcirculation, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Ceramides and chronic kidney disease (CKD) independently associate with coronary microvascular dysfunction (CMD), but their combined association remains unestablished, warranting investigation.
Methods
This cross-sectional analysis included coronary artery disease (CAD) patients from the CRUISE-MET trial (NCT06383208) who underwent coronary angiography and ceramide profiling measurement. The microvascular resistance was assessed in all patients using the angiography-derived microcirculatory resistance (AMR). CKD was classified based on both estimated glomerular filtration rate and urine albumin-to-creatinine ratio. The combined associations and statistical mediation of ceramides and renal dysfunction on CMD was examined, with sensitivity analyses to ensure the robustness.
Results
In this analysis of 794 CAD patients, CKD patients demonstrated significantly higher AMR values (2.56 ± 0.51 vs. 2.46 ± 0.48, p = 0.003) and CMD prevalence (57.1% vs. 41.7%, p < 0.001). Three ceramide species – Cer(18:1/16:0), Cer(18:1/18:0), and Cer(18:1/24:1) – showed strong positive correlations with AMR (all p < 0.05). LASSO regression identified 14 factors associated with CMD, with E/e′, CKD, and Cer(18:1/16:0) emerging as top correlates. Cer(18:1/16:0) demonstrated superior predictive performance (area under the curve [AUC] = 0.609, 95% CI: 0.570–0.648, p < 0.001), with its addition to baseline models significantly improving reclassification (δAUC = 0.03, p = 0.010; cNRI>0 = 0.23, p < 0.001; integrated discrimination improvement = 0.03, p < 0.001). Notably, patients with concurrent CKD and elevated Cer(18:1/16:0) exhibited significantly higher odds of CMD (OR = 3.74, 95% CI: 2.39–5.84). Statistical mediation analysis suggested that Cer(18:1/16:0) mediated 13.8% of the association between CKD and CMD.
Conclusion
Ceramides, particularly Cer(18:1/16:0), partially mediated the statistical association between CKD and CMD. These findings highlight the potential role of sphingolipid metabolism in cardiorenal pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.
- Department of Cardiology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.
- China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, mdjingangzheng@yeah.net.
- Department of Cardiology, China-Japan Friendship Hospital, Beijing, China, mdjingangzheng@yeah.net.
- Department of Cardiology, China-Japan Friendship Hospital, Beijing, China, gaoyx1980@163.com.
Zitieren
APA
Chen, Q., Li, X., Xie, Y., Li, Y., Sheng, Z., Che, W., An, S., Fu, S., He, L., Fang, C., Dong, W., Zheng, J., & Gao, Y. (2026). Chronic Kidney Disease, Circulating Ceramides, and Coronary Microvascular Dysfunction: Insights from the CRUISE-MET Study. Cardiorenal Medicine. https://doi.org/10.1159/000552268
Vancouver
Chen Q, Li X, Xie Y, Li Y, Sheng Z, Che W, et al. Chronic Kidney Disease, Circulating Ceramides, and Coronary Microvascular Dysfunction: Insights from the CRUISE-MET Study. Cardiorenal Medicine. 2026. doi:10.1159/000552268
BibTeX
@article{Chen2026,
author = {Chen, Qiang and Li, Xuexi and Xie, Yingying and Li, Yike and Sheng, Zhaoxue and Che, Wuqiang and An, Shuoyan and Fu, Sunjing and He, Lining and Fang, Cui and Dong, Wenjun and Zheng, Jingang and Gao, Yanxiang},
title = {Chronic Kidney Disease, Circulating Ceramides, and Coronary Microvascular Dysfunction: Insights from the CRUISE-MET Study},
journal = {Cardiorenal Medicine},
year = {2026},
doi = {10.1159/000552268}
}
EUVIMED